Replies to post #2101 on Biotech Values

[10nisman]

Dew,

How much would an intravenous injection/dosing cost? One would have to think that MediCare/Insurance companies would pull more weight than the doctors, if the cost of deliverying a similar effective drug (i.e., Squalamine) was a lot cheaper.

I guess the doctors wouldn't have to use Squalamine, however, why wouldn't Medicare/Insurance lower its coverage rates thus forcing doctors to use Squalamine or a cheaper yet as effective drug.

Do you think patients would have anything to say in the matter?

Thanks. 10nis.

[mskatiescarletohara]

Dew and Tennisman...Medicare/EYET

Has there been any speculation yet on the potential cost of Squalamine? I assume this is still being fine tuned given the Phase II studies are just now enrolling to achieve optimal dosing results.

Does GENR have their contract manufacturing squared away yet? This is very important at this stage in development. I haven't read the K with a magnifying glass, and haven't spoke to IR.

With respect to Medicare, they have interviewed Dr. Levitt, at this juncture we can only assume Squalamine is on it's "watch-list", and they very well could endorse this drug if it's cheap and obviously safer. The Oliver Stone in me says the FDA and Medicare conspire together if they want something.

If Squalamine performs well in the Phase II and pivotals, GENR will clearly need a strong sales force in place with the eye docs. By the way----Squalamine needs a trademark name!

See-Again!

katie...